stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Shares outstanding
Viridian Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $84.8M, up 24.9% from $67.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $107.9M. Over the past ten years it has ranged from $36.0K (fiscal 2015) to $84.8M (fiscal 2025) — the current reading is the highest in ten years. Viridian Therapeutics, Inc. ranks 130th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $84.8M | 24.92% |
| FY2024 | $67.9M | 51.68% |
| FY2023 | $44.8M | 39.48% |
| FY2022 | $32.1M | 169.21% |
| FY2021 | $11.9M | 235.09% |
| FY2020 | $3.6M | 70.27% |
| FY2019 | $2.1M | 5.81% |
| FY2018 | $2.0M | 53.81% |
| FY2017 | $1.3M | 3,030.73% |
| FY2016 | $41.0K | 13.89% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $107.9M | 5.55% |
| Mar 2026 | $102.2M | 20.53% |
| Dec 2025 | $84.8M | 3.69% |
| Sep 2025 | $81.8M | 0.23% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| DNLI Denali Therapeutics Inc. compare | $192.1M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| VRDN Viridian Therapeutics, Inc. | $107.9M |
| IDYA IDEAYA Biosciences, Inc. compare | $102.9M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement